Results retrieved from the PRISM further revealed that although an elevated expression of HRAS significantly increased (Pearson correlation: <−0.4) the sensitivity (the lower the log2 change is, the higher the sensitivity is) of bladder cancer cell lines to gemcitabine, it had no beneficial effect against cisplatin (Figure 1C), implying that the basis of poor clinical outcome in patients receiving the current standard first-line combination therapy of cisplatin and gemcitabine [3] may be due to cisplatin-insensitivity of cells overexpressing the HRAS gene. Here, HRAS is linked to urinary bladder carcinoma.